Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

• Published in: Inflammatory bowel diseases Vol. 26; no. 10; pp. 1597 - 1606
• Main Authors: Batra, Suruchi K, Heier, Christopher R, Diaz-Calderon, Lina, Tully, Christopher B, Fiorillo, Alyson A, van den Anker, John, Conklin, Laurie S
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.10.2020
• Subjects: Biological markers; Children; Clinical Research; Corticosteroids; Diseases; Medical research; Medicine, Experimental; MicroRNA; Tumor necrosis factor; Ulcerative colitis; microRNA; pharmacodynamic; biomarker; inflammatory bowel disease
• ISSN: 1078-0998; 1536-4844
• DOI: 10.1093/ibd/izaa209

Abstract Background We sought to identify microRNAs (miRNAs) associated with response to anti-TNF-α or glucocorticoids in children with inflammatory bowel disease (IBD) to generate candidate pharmacodynamic and monitoring biomarkers. Methods Clinical response was assessed by Pediatric Crohn’s Disease Activity Index and Pediatric Ulcerative Colitis Activity Index. Quantitative real-time polymerase chain reaction via Taqman Low-Density Array cards were used to identify miRNAs in a discovery cohort of responders (n = 11) and nonresponders (n = 8). Seven serum miRNAs associated with clinical response to treatment, along with 4 previously identified (miR-146a, miR-146b, miR-320a, miR-486), were selected for further study. Candidates were assessed in a validation cohort of serum samples from IBD patients pre- and post-treatment and from healthy controls. Expression of miRNA was also analyzed in inflamed mucosal biopsies from IBD patients and non-IBD controls. Results Discovery cohort analysis identified 7 miRNAs associated with therapeutic response: 5 that decreased (miR-126, miR-454, miR-26b, miR-26a, let-7c) and 2 that increased (miR-636, miR-193b). In the validation cohort, 7 of 11 candidate miRNAs changed in the same direction with response to anti-TNF-α therapies, glucocorticoids, or both. In mucosal biopsies, 7 out of 11 miRNAs were significantly increased in IBD vs healthy controls. Conclusions Five candidate miRNAs associated with clinical response and mucosal inflammation in pediatric IBD patients were identified (miR-126, let-7c, miR-146a, miR-146b, and miR-320a). These miRNAs may be further developed as pharmacodynamic and response monitoring biomarkers for use in clinical care and trials. Discovery and validation cohort analyses were conducted to identify serum microRNAs associated with therapeutic response. Plausibility was refined by evaluation of expression in inflamed mucosal biopsies. Five serum pharmacodynamic and candidate monitoring biomarkers for pediatric IBD were identified.